Enliven Therapeutics, Inc.

About Enliven Therapeutics, Inc.

Enliven Therapeutics is dedicated to advancing medicine and restoring lives, with a mission to help people with cancer live longer and better through the development of innovative therapies.

Products & Services

BCR-ABL Program:A targeted kinase inhibitor program focused on addressing specific cancer mutations.

Additional Programs:Other ongoing kinase inhibitor programs for various cancer treatments.

ELVN-001

Specialties

Small Molecule Kinase Inhibitors Cancer Therapeutics Precision Medicine Drug Discovery and Development small molecule drug discovery precision therapeutics oncology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 460000000 MR: - FA: $460 million FAN: 460000000	D: 2026-06-15 FD: 2026-06-15	8 investors
2	RT: Public Offering T: - FT: Public Offering	A: 250000000 MR: - FA: $250 million FAN: 250000000	D: 2026-06-11 FD: 2026-06-11	-
3	RT: Public Offering T: - FT: Public Offering	A: 400000000 MR: - FA: $400.0 million FAN: 400000000	D: 2026-06-11 FD: 2026-06-11	8 investors
4	RT: Public Offering of Common Stock and Pre-Funded Warrants T: - FT: Public Offering of Common Stock and Pre-Funded Warrants	A: 230000000 MR: - FA: $230 million FAN: 230000000	D: 2025-06-16 FD: 2025-06-16	5 investors
5	RT: Public Offering of Common Stock and Pre-Funded Warrants T: - FT: Public Offering of Common Stock and Pre-Funded Warrants	A: 200000000 MR: - FA: $200 million FAN: 200000000	D: 2025-06-13 FD: 2025-06-13	5 investors
6	RT: Public Offering T: - FT: Public Offering	A: 200000000 MR: - FA: $200 million FAN: 200000000	D: 2025-06-13 FD: 2025-06-13	5 investors
7	RT: PIPE T: - FT: PIPE	A: 90000000 MR: - FA: 90 million FAN: 90000000	D: 2024-03-19 FD: 2024-03-19	9 investors

Public Offering Latest

2026-06-15

$460.0M

8 investors (Pro only)

Public Offering 2026-06-11

$250.0M

Public Offering 2026-06-11

$400.0M

View 6 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Rick Fair

Chief Executive Officer and Member of the Board of Directors

S

Sam Kintz

Co-founder and Head of Pipeline

J

Joe Lyssikatos

Co-founder and Research Fellow

A

Anish Patel

Co-founder and Chief Operating Officer

H

Helen Collins

Chief Medical Officer

B

Ben Hohl

Chief Financial Officer and Head of Corporate Development

View 61 more team members with Pro

Unlock Full Team Directory

Recent News